[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642649":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":40,"centralContacts":44,"locations":54,"responsibleParty":72,"collaborators":75,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":28,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":28,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":28,"overallStatus":98,"whyStopped":28,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Endeavor Health","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"aprepitant","EXPERIMENTAL","Single intravenous (IV) bolus of 32mg aprepitant preoperatively , in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)",[13,14,15],"Drug: Aprepitant Injection","Drug: Ondansetron (Zofran)","Drug: Dexamethasone",{"label":17,"type":18,"description":19,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR","Single intravenous (IV) bolus of 32mg of placebo preoperatively, in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)",[14,15,21],"Other: Placebo",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Aprepitant Injection","32mg aprepitant will be administered intravenously preoperatively during single sided total knee arthroscopy",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Ondansetron (Zofran)","4 mg IV ondansetron will be given at surgical closure during total knee arthroscopy",[17,9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Dexamethasone","4 mg IV dexamethasone will be given after induction of MAC sedation anesthesia during total knee arthroscopy",[17,9],{"type":6,"name":17,"description":38,"armGroupLabels":39,"otherNames":28},"Patients will receive 32 mg of intravenous (IV) placebo preoperatively for a total knee arthroscopy",[17],[41],{"name":42,"affiliation":5,"role":43},"Steven Greenberg, MD","PRINCIPAL_INVESTIGATOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":28,"email":49},"Jessica Brickner","CONTACT","847-570-1197","jessica.brickner@endeavorhealth.org",{"name":51,"role":47,"phone":52,"phoneExt":28,"email":53},"Nia Moragne","084-570-1197","nia.moragne@endeavorhealth.org",[55],{"facility":56,"status":28,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Endeavor Health Skokie Hospital","Skokie","Illinois","60076","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-87.73339,42.03336,{"lat":66,"lon":65},[69,70,71],{"name":46,"role":47,"phone":48,"phoneExt":28,"email":49},{"name":51,"role":47,"phone":48,"phoneExt":28,"email":53},{"name":42,"role":43,"phone":28,"phoneExt":28,"email":28},{"type":43,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Steven Greenberg","Jeffery S. Vender, MD, Chair of Anesthesiology Research and Education Endeavor Health Clinical Professor, Pritzker School of Medicine The University of Chicago",[76],{"name":77,"class":78},"Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.)","UNKNOWN","100642649","phase-4-aprepitant-to-improve-same-day-discharge-for-tka-100642649",false,"NCT07639723","Aprepitant to Improve Same Day Discharge for TKA","Preoperative Aprepitant to Improve Same-Day Discharge After Total Knee Arthroplasty: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Receiving primary, unilateral elective TKA with or without abductor canal block\n* Asa I-III\n* Age 18-90\n* Ability to receive ondansetron and dexamethasone\n* Ability to consent and complete surveys\n* English or Spanish speaking\n* Receiving regional anesthesia (epidural or spinal) for surgery\n\nExclusion Criteria:\n\n* Allergy to any of the anti-emetics being administered\n* Current treatment of pimozide\n* Emergent surgery\n* Revision\u002F multiple revisions of TKA\n* Clinical suspicion of possible bowel obstruction\n* Need for general anesthesia\n* Pregnant\u002Fbreast feeding\n* AST\\> 2.5 x the upper limit of normal or ALT\\> 2.5 x upper limit of normal, bilirubin\\> 1.5x upper limit of normal\n* Need for opioid or benzodiazepine antagonists\n* Not planned for same day discharge\n* Enrollment in a different drug trial for TKA\n* Unable to consent in English or Spanish","ALL","18 Years","90 Years",{"count":90,"type":91},350,"ESTIMATED","INTERVENTIONAL",[94],"PHASE4","The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.",[97],"PONV","NOT_YET_RECRUITING","2026-06-06",{"date":101,"type":102},"2026-06-10","ACTUAL",{"date":104,"type":91},"2026-07",{"date":106,"type":91},"2027-08",{"name":5,"class":6},1]